ECOG E2100 - Cancer Therapy Evaluation Program (CTEP)

14.07.2013 • Views

Share Embed Flag

ECOG E2100 - Cancer Therapy Evaluation Program (CTEP)

ECOG E2100 - Cancer Therapy Evaluation Program (CTEP)

DOWNLOAD ePAPER

ctep.cancer.gov

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

Caucasians African-Americans

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

CTEP Personnel - Cancer Therapy Evaluation Program (CTEP)

Femara Tablets - Cancer Therapy Evaluation Program (CTEP)

2012 CTMB Audit Guidelines - Cancer Therapy Evaluation Program ...

Common Toxicity Criteria - Cancer Therapy Evaluation Program ...

MATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION ...

Material Safety Data Sheet Page 1 07 Sept 2007 AFLIBERCEPT ...

Cancer Therapy Evaluation Program 3.0 CTCAE Version From 2.0 ...

Common Terminology Criteria for Adverse Events (CTCAE) v3.0 ...

ctep, nci guidelines: adverse event reporting requirements - Cancer ...

Preoperative Chemotherapy, NSABP Protocols B-18 and B-27: an ...

Cover Letter for NCI Consent Form Template - Cancer Therapy ...

CTCAE v4.0 SOC MedDRA v12.0 Code - Cancer Therapy ...

NCI National Clinical Trials Network (NCTN) Program Guidelines

ADVERSE EVENT EXPEDITED REPORT List of Values - Cancer ...

Caucasians African-Americans

Caucasians African-Americans 76% 70% 47%

Page 1 and 2: ECOG Pharmacogenomics: Anti-Angioge
Page 3 and 4: Genetic variability impacts angioge
Page 5 and 6: Bevacizumab in breast cancer-E2100:
Page 7 and 8: PFS Proportion 1.0 0.8 0.6 0.4 0.2
Page 9 and 10: GOOD NEWS=all subgroups gained bene
Page 11 and 12: Germline genetic variation in tumor
Page 13 and 14: Candidate SNPs meet fundamental •
Page 15 and 16: Genetic variability in tumor angiog
Page 17 and 18: VEGF -2578 AA & -1154 AA genotypes
Page 19 and 20: Genetic variability of VEGF predict
Page 21 and 22: VEGF genotypes may be associated wi
Page 23: VEGF Promoter & 5’-UTR Re-sequenc
Page 27 and 28: Acknowledgements • David Flockhar